25 January 2016 - Amgen today announced that the U.S. FDA has accepted for review Amgen's biologics license application for ABP 501, a biosimilar candidate to Humira (adalimumab).

For more details, go to: http://www.amgen.com/media/news-releases/2016/01/fda-accepts-amgens-biosimilar-biologics-license-application-for-abp-501/